Browse Drug Recalls
151 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 151 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 151 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Oct 2, 2023 | 1% Lidocaine HCl Injection, USP, 50mg/5mL(10mg/mL), Glass ABBOJECT Unit of Us... | Presence of Particulate Matter: identified as glass. | Class I | Pfizer Inc. |
| Oct 2, 2023 | 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJEC... | Presence of Particulate Matter: identified as glass. | Class I | Pfizer Inc. |
| Oct 2, 2023 | 2% Lidocaine HCl Injection, USP, 100mg/5mL(20mg/mL), Glass ABBOJECT Unit of U... | Presence of Particulate Matter: identified as glass. | Class I | Pfizer Inc. |
| Jun 4, 2018 | Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL Carpuject Si... | Presence of Particulate Matter; Potential for particulate matter on the syringe plunger. | Class I | HOSPIRA INC, LAKE FOREST |
| Feb 20, 2018 | Labetalol Hydrochloride Injection, USP, 100 mg/ 20 mL (5 mg/mL), 20 mL Multid... | Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and ... | Class II | Hospira Inc. A Pfizer Company |
| Jul 6, 2017 | Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 5 mL Single-use vial, Rx Onl... | Failed Impurities/Degradation Specifications; out of specification result for denitroquinoline-re... | Class III | Hospira Inc., A Pfizer Company |
| May 18, 2017 | Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx o... | GMP Deviation; A foreign stopper was observed during packaging of a lot of product. | Class II | Hospira Inc., A Pfizer Company |
| Apr 21, 2017 | Infant 25% DEXTROSE Injection, USP, 2.5 g (250 mg/mL), 10 mL Unit of Use Sing... | Presence of Particulate Matter: human hair found within an internal sample syringe. | Class I | Hospira Inc. |
| Feb 10, 2017 | METRONIDazole Injection, USP 500 mg (5 mg/mL) in 100 mL Single Dose Flexible ... | Lack of Sterility Assurance: customer report of leaking bag | Class II | Hospira Inc., A Pfizer Company |
| Jan 24, 2017 | Vancomycin Hydrochloride for Injection, USP, 10 grams, Pharmacy Bulk Package ... | Presence of Particulate Matter: A hair was found stuck to the stopper of inside a single vial. Th... | Class I | Hospira Inc., A Pfizer Company |
| Nov 1, 2016 | Fentanyl Citrate Injection, USP, 100 mcg Fentanyl/ 2mL, Single Dose, 50 mcg/m... | Lack of Assurance of Sterility: Complaints of broken tips on the ampules. | Class II | Hospira Inc. |
| Sep 16, 2016 | Marcaine 0.5% (bupivacaine HCl) injection, USP, 250 mg/50 mL (5 mg/mL), 50 mL... | Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from fo... | Class II | Hospira Inc., A Pfizer Company |
| Sep 16, 2016 | Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50... | Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from fo... | Class II | Hospira Inc., A Pfizer Company |
| Aug 15, 2016 | DOBUTamine Injection, USP 250 mg/20 mL, 20 mL Vial, For IV Use Only, Must be ... | Discoloration: Firm received complaints of product discoloration and particulates. | Class II | Hospira Inc. |
| Aug 4, 2016 | Bupivacaine Hydrochloride Inj., USP (2.5 mg/mL) 0.25%, packaged in 30 mL Sing... | Presence of particulate matter: Confirmed customer report for the presence of particulate matter ... | Class I | Hospira Inc., A Pfizer Company |
| Jun 29, 2016 | 5% Lidocaine HCL and 7.5% Dextrose Injection, USP, 2 mL Single-dose ampule, 5... | Failed Stability Specifications: The recalled lots did not meet the specification for color and p... | Class III | Hospira Inc. |
| Jun 23, 2016 | Diazepam Injection USP 10mg/2mL (5 mg/mL, 2 mL), Rx only, Hospira Inc. Lake ... | Crystallization: Product contains particulate identified to be crystallized active ingredient. | Class II | Hospira Inc. |
| May 6, 2016 | Vancomycin Hydrochloride for Injection, USP, 10 g, 100 mL vial, Rx only, Hosp... | Presence of Particulate Matter: Cardboard | Class II | Hospira Inc. |
| Mar 23, 2016 | Magnesium Sulfate Inj., USP 50%, 10 g/20 mL (0.5 g/mL), (4 mEq Magnesium/mL, ... | Failed pH Specifications: Confirmed high out of specification (OOS) results for pH. | Class III | Hospira Inc. |
| Mar 23, 2016 | Magnesium Sulfate Inj., USP 50%, 10 g/20 mL (0.5 g/mL), (4 mEq Magnesium/mL, ... | Presence of Particulate Matter: Confirmed customer complaint for the presence of particulate matter. | Class I | Hospira Inc. |
| Mar 18, 2016 | 8.4% Sodium Bicarbonate Injection, USP 50mEq (1mEq/mL), 4.2 grams (84 mg/mL),... | Presence of Particulate Matter: particulate matter identified as an insect in one vial. | Class I | Hospira Inc. |
| Mar 15, 2016 | Quelicin (Succinylcholine Chloride) Injection, USP 200 mg. (20 mg/mL), 10 mL ... | Labeling: Incorrect or Missing Lot and/or Exp Date: Potential for the lot number and/or expiratio... | Class III | Hospira Inc. |
| Mar 8, 2016 | Aminosyn-PF (amino acids) 7%, Sulfite-Free, 500 mL Bags, Rx Only, Hospira, In... | Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon ... | Class II | Hospira Inc. |
| Mar 8, 2016 | Potassium Chloride Injection 20 mEq, 400 mEq/L, Packaged in 50 mL Bags, Rx on... | Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon ... | Class II | Hospira Inc. |
| Mar 8, 2016 | Dextrose Injection, USP, 70%, Packaged as 500 mL in 1000 mL Bag, Rx only, Ho... | Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon ... | Class II | Hospira Inc. |
| Mar 8, 2016 | Dextrose Injection, USP, 50%, Packaged as 500 mL in 1000 mL Bag, Rx only, Hos... | Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon ... | Class II | Hospira Inc. |
| Mar 8, 2016 | Mannitol I.V., 20%, USP (20 g/ 100 mL), Packaged in 250 mL Bags, Rx Only, Hos... | Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon ... | Class II | Hospira Inc. |
| Mar 8, 2016 | Dextrose Injection, USP, 20%, Packaged as 500 mL in 1000 mL Bags, Rx only, Ho... | Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon ... | Class II | Hospira Inc. |
| Feb 2, 2016 | Normosol-M and 5% Dextrose (multiple electrolytes and 5% dextrose) Injection ... | Labeling: Incorrect or Missing Lot and/or Exp Date: Confirmed customer report of an incorrect exp... | Class III | Hospira Inc. |
| Jan 5, 2016 | Magnesium Sulfate in Water for Injection, (0.325 mEq Mg++/mL) 40 mg/mL, 2 g T... | Labeling: Incorrect Barcode: Primary bag labeling may be mislabeled with the wrong barcode which ... | Class I | Hospira Inc. |
| Sep 29, 2015 | Amidate (Etomidate Injection, USP), 40 mg/20 mL (2 mg/mL), LifeShield, 20 mL,... | Failed Impurities/Degradation Specifications: Out of Specification(OOS) results for degradation p... | Class III | Hospira Inc. |
| Aug 20, 2015 | Ketamine Hydrochloride Injection, USP (100 mg/mL) packaged in 5 mL multi-dose... | Defective Container: There were customer complaints of cracked and leaking glass vials. | Class II | Hospira Inc. |
| Jul 2, 2015 | 0.9% Sodium Chloride Injection USP, 50 mL ADD-Vantage Unit, Rx only, Manufact... | Lack of assurance of sterility: Potential channel leaks near the threaded vial port. | Class II | Hospira Inc. |
| Jun 30, 2015 | KETOROLAC Tromethamine Inj., USP, 60 mg (30 mg/mL), 2 mL Fill Single-dose Via... | Crystallization; identified as calcium salt of Ketorolac | Class II | Hospira Inc. |
| Jun 30, 2015 | KETOROLAC Tromethamine Inj., USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose Vi... | Crystallization; identified as calcium salt of Ketorolac | Class II | Hospira Inc. |
| May 19, 2015 | Magnesium Sulfate Injection, USP, 50%, 20mL, Single dose Fliptop Vial, For IV... | Failed pH Specifications: 12 month stability testing | Class III | Hospira Inc. |
| Apr 23, 2015 | Bupivacaine Hydrochloride Inj., USP, 0.5% (5 mg/mL), Preservative-Free, 30 mL... | Presence of Particulate Matter: Presence of free-floating and embedded iron oxide particles. | Class I | Hospira Inc. |
| Apr 13, 2015 | Ketorolac Tromethamine Inj. USP, 60 mg (30 mg/mL), 2 mL Fill, Single-dose via... | Crystallization | Class II | Hospira Inc. |
| Apr 13, 2015 | Ketorolac Tromethamine Inj. USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose via... | Crystallization | Class II | Hospira Inc. |
| Apr 7, 2015 | 0.9% Sodium Chloride Injection, USP, 100 mL ADD-Vantage Unit, Rx only, Manufa... | Lack of Sterility Assurance: The product has the potential to leak at the administrative port. | Class II | Hospira Inc. |
| Mar 11, 2015 | LACTATED RINGER'S IRRIGATION, USP, 3000 mL flexible container bag, Rx Only, M... | Non-Sterility: Confirmed customer report of dark, fibrous particulates floating within the soluti... | Class I | Hospira Inc. |
| Mar 6, 2015 | MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION, USP, 10 mg/mL; 100 mL bag, Rx onl... | Labeling: Wrong Bar Code: There is a potential for some units to be mislabeled with an incorrect ... | Class I | Hospira Inc. |
| Mar 5, 2015 | 5% DEXTROSE Injection, USP, 250 mL ADD-Vantage Unit bag (NDC 0409-7100-02), U... | Lack of Assurance of Sterility: there is a potential for solution to leak at the administrative p... | Class II | Hospira Inc. |
| Mar 5, 2015 | 0.9% Sodium Chloride Injection, USP, 250 mL, Rx only, VisIV Container, Hospi... | Presence of Particulate Matter: Confirmed finding of human hair floating in IV solution. | Class I | Hospira Inc. |
| Jan 23, 2015 | KETOROLAC Tromethamine Inj., USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose Vi... | Crystallization | Class II | Hospira Inc. |
| Jan 23, 2015 | KETOROLAC Tromethamine Inj., USP, 60 mg (30 mg/mL), 2 mL Fill Single-dose Via... | Crystallization | Class II | Hospira Inc. |
| Jan 20, 2015 | 0.9% Sodium Chloride Injection, USP, 250 mL, Rx Only, Hospira Inc., Lake Fore... | Presence of Particulate Matter; Hospira has identified the particulate as a human hair, sealed in... | Class I | Hospira Inc. |
| Dec 23, 2014 | Propofol Injectable Emulsion, 1%, 200 mg/20 mL, (10mg/mL), 20 mL, Single pati... | Presence of Particulate Matter: The firm received a complaint of an embedded particulate in the n... | Class II | Hospira Inc. |
| Dec 22, 2014 | 0.9% Sodium Chloride Injection, USP, 100mL, VisIV Container, Rx only, Hospira... | Lack of Assurance of Sterility: The product has the potential for solution to leak at the adminis... | Class II | Hospira Inc. |
| Dec 3, 2014 | Fentanyl Citrate Injection, USP, 2500 mcg Fentanyl/50 mL, 50 mL Single-dose F... | Lack of Assurance of Sterility; improperly crimped fliptop vials | Class II | Hospira Inc. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.